GDNF Contributes to Oestrogen-Mediated Protection of Midbrain Dopaminergic Neurones

Journal of Neuroendocrinology

Volumn 24, Issue 11, 2012, Pages 1386-1397

  Campos, F L ^a,b   Cristovao A C ^a   Rocha, S M ^a   Fonseca, C P ^a   Baltazar, G ^a  

^a UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^b UNIVERSITY OF MINHO   (Portugal)

Author keywords

6 hydroxydopamine; Astrocytes; Dopaminergic cells; Oestradiol; Parkinson's disease

Indexed keywords

ALPHA TUBULIN; ESTRADIOL; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; OXIDOPAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; EMBRYO; GENE EXPRESSION REGULATION; GENE SILENCING; GLIA; IN VIVO STUDY; MALE; MESENCEPHALON; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OSMOTIC PUMP; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RNA INTERFERENCE; SUBSTANTIA NIGRA;

ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; CYTOPROTECTION; DOPAMINERGIC NEURONS; EMBRYO, MAMMALIAN; ESTRADIOL; ESTROGENS; FEMALE; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; MALE; MESENCEPHALON; OXIDOPAMINE; PREGNANCY; RATS; RATS, WISTAR; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84867668559     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2012.02348.x     Document Type: Article

References (63)

1. Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson's disease than women?J Neurol Neurosurg Psychiatry 2004; 75: 637-639.
2. Growdon JH, Kieburtz K, McDermott MP, Panisset M, Friedman JH. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson study group. Neurology 1998; 50: 1327-1331.
3. Lyons KE, Hubble JP, Troster AI, Pahwa R, Koller WC. Gender differences in Parkinson's disease. Clin Neuropharmacol 1998; 21: 118-121.
4. Zappia M, Annesi G, Nicoletti G, Arabia G, Annesi F, Messina D, Pugliese P, Spadafora P, Tarantino P, Carrideo S, Civitelli D, De Marco EV, Ciro-Candiano IC, Gambardella A, Quattrone A. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch Neurol 2005; 62: 601-605.
5. Dluzen DE. Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system. J Neurocytol 2000; 6: 387-399.
6. Al-Sweidi S, Morissette M, Bourque M, Di Paolo T. Estrogen receptors and gonadal steroids in vulnerability and protection of dopamine neurons in a mouse model of Parkinson's disease. Neuropharmacology 2011; 61: 583-591.
7. Gillies GE, McArthur S. Independent influences of sex steroids of systemic and central origin in a rat model of Parkinson's disease: a contribution to sex-specific neuroprotection by estrogens. Horm Behav 2010; 57: 23-34.
8. Murray HE, Pillai AV, McArthur SR, Razvi N, Datla KP, Dexter DT, Gillies GE. Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females. Neuroscience 2003; 116: 213-222.
9. Callier S, Le Saux M, Lhiaubet AM, Di Paolo T, Rostene W, Pelaprat D. Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (Mpp+) towards dopaminergic mesencephalic neurones in primary culture. J Neurochem 2002; 80: 307-316.
10. Dluzen DE, McDermott JL, Liu B. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. Neurotoxicol Teratol 1996; 18: 603-606.
11. Ramirez AD, Liu X, Menniti FS. Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice. Neuroendocrinology 2003; 77: 223-231.
12. Sawada H, Ibi M, Kihara T, Urushitani M, Akaike A, Shimohama S. Estradiol protects mesencephalic dopaminergic neurons from oxidative stress-induced neuronal death. J Neurosci Res 1998; 54: 707-719.
13. Behl C, Skutella T, Lezoualc'h F, Post A, Widmann M, Newton CJ, Holsboer F. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol 1997; 51: 535-541.
14. Sawada H, Ibi M, Kihara T, Urushitani M, Honda K, Nakanishi M, Akaike A, Shimohama S. Mechanisms of antiapoptotic effects of estrogens in nigral dopaminergic neurons. FASEB J 2000; 14: 1202-1214.
15. Harms C, Lautenschlager M, Bergk A, Katchanov J, Freyer D, Kapinya K, Herwig U, Megow D, Dirnagl U, Weber JR, Hortnagl H. Differential mechanisms of neuroprotection by 17 beta-estradiol in apoptotic versus necrotic neurodegeneration. J Neurosci 2001; 21: 2600-2609.
16. Ivanova T, Karolczak M, Beyer C. Estradiol stimulates GDNF expression in developing hypothalamic neurons. Endocrinology 2002; 143: 3175-3178.
17. Gibbs RB. Treatment with estrogen and progesterone affects relative levels of brain-derived neurotrophic factor mRNA and protein in different regions of the adult rat brain. Brain Res 1999; 2: 20-27.
18. Pan M, Li Z, Yeung V, Xu RJ. Dietary supplementation of soy germ phytoestrogens or estradiol improves spatial memory performance and increases gene expression of BDNF, TrkB receptor and synaptic factors in ovariectomized rats. Nutr Metab (Lond) 2010; 7: 75.
19. Pietranera L, Lima A, Roig P, De Nicola AF. Involvement of brain-derived neurotrophic factor and neurogenesis in oestradiol neuroprotection of the hippocampus of hypertensive rats. J Neuroendocrinol 2010; 22: 1082-1092.
20. Zhou J, Zhang H, Cohen RS, Pandey SC. Effects of estrogen treatment on expression of brain-derived neurotrophic factor and cAMP response element-binding protein expression and phosphorylation in rat amygdaloid and hippocampal structures. Neuroendocrinology 2005; 81: 294-310.
21. Dittrich F, Feng Y, Metzdorf R, Gahr M. Estrogen-inducible, sex-specific expression of brain-derived neurotrophic factor mRNA in a forebrain song control nucleus of the juvenile zebra finch. Proc Nat Acad Sci USA 1999; 96: 8241-8246.
22. Ivanova T, Kuppers E, Engele J, Beyer C. Estrogen stimulates brain-derived neurotrophic factor expression in embryonic mouse midbrain neurons through a membrane-mediated and calcium-dependent mechanism. J Neurosci Res 2001; 66: 221-230.
23. Kang J, Qian PX, Pandey V, Perry JK, Miller LD, Liu ET, Zhu T, Liu DX, Lobie PE. Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma. Oncogene 2010; 29: 3228-3240.
24. Garcia-Segura LM, Diz-Chaves Y, Perez-Martin M, Darnaudery M. Estradiol, insulin-like growth factor-I and brain aging. Psychoneuroendocrinology 2007; 32(Suppl 1): S57-S61.
25. Hoffer BJ, Hoffman A, Bowenkamp K, Huettl P, Hudson J, Martin D, Lin LF, Gerhardt GA. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 1994; 182: 107-111.
26. Lapchak PA, Miller PJ, Collins F, Jiao S. Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery. Neuroscience 1997; 78: 61-72.
27. Bowenkamp KE, Lapchak PA, Hoffer BJ, Miller PJ, Bickford PC. Intracerebroventricular glial cell line-derived neurotrophic factor improves motor function and supports nigrostriatal dopamine neurons in bilaterally 6-hydroxydopamine lesioned rats. Exp Neurol 1997; 145: 104-117.
28. Paxinos G, Watson C. The rat brain in stereotaxic coordinates Amsterdam; Boston: Elsevier, 2007.
29. Burke RE, Antonelli M, Sulzer D. Glial cell line-derived neurotrophic growth factor inhibits apoptotic death of postnatal substantia nigra dopamine neurons in primary culture. J Neurochem 1998; 71: 517-525.
30. Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, Green DR. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 1995; 182: 1545-1556.
31. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Nat Acad Sci USA 1996; 93: 2696-2701.
32. Sawada H, Shimohama S. Neuroprotective effects of estradiol in mesencephalic dopaminergic neurons. Neurosci Biobehav Rev 2000; 24: 143-147.
33. Bains M, Cousins JC, Roberts JL. Neuroprotection by estrogen against MPP+-induced dopamine neuron death is mediated by ERalpha in primary cultures of mouse mesencephalon. Exp Neurol 2007; 204: 767-776.
34. Callier S, Morissette M, Grandbois M, Di Paolo T. Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice. Synapse 2000; 37: 245-251.
35. Dluzen D. Estrogen decreases corpus striatal neurotoxicity in response to 6-hydroxydopamine. Brain Res 1997; 767: 340-344.
36. Bourque M, Dluzen DE, Di Paolo T. Neuroprotective actions of sex steroids in Parkinson's disease. Front Neuroendocrinol 2009; 30: 142-157.
37. Liu B, Dluzen DE. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease. Clin Exp Pharmacol Physiol 2007; 34: 555-565.
38. Cordellini MF, Piazzetta G, Pinto KC, Delattre AM, Matheussi F, Carolino RO, Szawka RE, Anselmo-Franci JA, Ferraz AC. Effect of different doses of estrogen on the nigrostriatal dopaminergic system in two 6-hydroxydopamine-induced lesion models of Parkinson's disease. Neurochem Res 2011; 36: 955-961.
39. Ferraz AC, Matheussi F, Szawka RE, Rizelio V, Delattre AM, Rigon P, Hermel Edo E, Xavier LL, Achaval M, Anselmo-Franci JA. Evaluation of estrogen neuroprotective effect on nigrostriatal dopaminergic neurons following 6-hydroxydopamine injection into the substantia nigra pars compacta or the medial forebrain bundle. Neurochem Res 2008; 33: 1238-1246.
40. Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF. Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol 2004; 61: 886-888.
41. Baldereschi M, Di Carlo A, Rocca WA, Vanni P, Maggi S, Perissinotto E, Grigoletto F, Amaducci L, Inzitari D. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian longitudinal study on aging. Neurology 2000; 55: 1358-1363.
42. Marder K, Tang MX, Mejia H, Alfaro B, Cote L, Louis E, Groves J, Mayeux R. Risk of Parkinson's disease among first-degree relatives: a community-based study. Neurology 1996; 47: 155-160.
43. Mayeux R, Denaro J, Hemenegildo N, Marder K, Tang MX, Cote LJ, Stern Y. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch Neurol 1992; 49: 492-497.
44. Kurtzke JF, Goldberg ID. Parkinsonism death rates by race, sex, and geography. Neurology 1988; 38: 1558-1561.
45. Garcia-Segura LM, Azcoitia I, DonCarlos LL. Neuroprotection by estradiol. Prog Neurobiol 2001; 63: 29-60.
46. Platania P, Seminara G, Aronica E, Troost D, Vincenza Catania M, Angela Sortino M. 17beta-estradiol rescues spinal motoneurons from AMPA-induced toxicity: a role for glial cells. Neurobiol Dis 2005; 20: 461-470.
47. Mitra SW, Hoskin E, Yudkovitz J, Pear L, Wilkinson HA, Hayashi S, Pfaff DW, Ogawa S, Rohrer SP, Schaeffer JM, McEwen BS, Alves SE. Immunolocalization of estrogen receptor beta in the mouse brain: comparison with estrogen receptor alpha. Endocrinology 2003; 144: 2055-2067.
48. Laflamme N, Nappi RE, Drolet G, Labrie C, Rivest S. Expression and neuropeptidergic characterization of estrogen receptors (ERalpha and ERbeta) throughout the rat brain: anatomical evidence of distinct roles of each subtype. J Neurobiol 1998; 36: 357-378.
49. Al Sweidi S, Sanchez MG, Bourque M, Morissette M, Dluzen D, Di Paolo T. Oestrogen receptors and signalling pathways: implications for neuroprotective effects of sex steroids in Parkinson's disease. J Neuroendocrinol 2012; 24: 48-61.
50. Brailoiu E, Dun SL, Brailoiu GC, Mizuo K, Sklar LA, Oprea TI, Prossnitz ER, Dun NJ. Distribution and characterization of estrogen receptor G protein-coupled receptor 30 in the rat central nervous system. J Endocrinol 2007; 193: 311-321.
51. Dluzen DE. Unconventional effects of estrogen uncovered. Trends Pharmacol Sci 2005; 26: 485-487.
52. Mooradian AD. Antioxidant properties of steroids. J Steroid Biochem Mol Biol 1993; 45: 509-511.
53. Cheng H, Fu Y-S, Guo J-W. Ability of GDNF to diminish free radical production leads to protection against kainate-induced excitotoxicity in hippocampus. Hippocampus 2004; 14: 77-86.
54. Chao CC, Lee EH. Neuroprotective mechanism of glial cell line-derived neurotrophic factor on dopamine neurons: role of antioxidation. Neuropharmacology 1999; 38: 913-916.
55. Saavedra A, Baltazar G, Carvalho CM, Duarte EP. GDNF modulates HO-1 expression in substantia nigra postnatal cell cultures. Free Radical Biol Med 2005; 39: 1611-1619.
56. Smith MP, Cass WA. GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson's disease. Neurosci Lett 2007; 412: 259-263.
57. Ratan RR, Murphy TH, Baraban JM. Oxidative stress induces apoptosis in embryonic cortical neurons. J Neurochem 1994; 62: 376-379.
58. Tan S, Wood M, Maher P. Oxidative stress induces a form of programmed cell death with characteristics of both apoptosis and necrosis in neuronal cells. J Neurochem 1998; 71: 95-105.
59. Przedborski S, Ischiropoulos H. Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease. Antioxid Redox Signal 2005; 6: 685-693.
60. Mochizuki H, Goto K, Mori H, Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci 1996; 137: 120-123.
61. Clarkson ED, Zawada WM, Freed CR. GDNF improves survival and reduces apoptosis in human embryonic dopaminergic neurons in vitro. Cell Tissue Res 1997; 289: 207-210.
62. Ding YM, Jaumotte JD, Signore AP, Zigmond MJ. Effects of 6-hydroxydopamine on primary cultures of substantia nigra: specific damage to dopamine neurons and the impact of glial cell line-derived neurotrophic factor. J Neurochem 2004; 89: 776-787.
63. Saavedra A, Baltazar G, Duarte EP. Driving GDNF expression: the green and the red traffic lights. Prog Neurobiol 2008; 86: 186-215.